CD40 ligand blockade

Much may be learnt about the suppression of autoimmunity using animal models of transplantation. The interaction between CD40 on B cells and CD40 ligand expressed predominantly by activated CD4⁺ T cells plays an important role in the development of the humoral immune response and the induction of peripheral tolerance. Monoclonal antibodies against CD4 and CD8 have been shown to induce CD4-regulated tolerance of mismatched transplanted tissues in rodents. These regulatory CD4⁺ cells also prevent the rejection of grafts, which co-express the antigens to which tolerance has been induced along with third party antigens. This phenomenon is known as linked suppression. The CD40/CD40L interaction is also an attractive target for immunotherapy, with the objective of inducing transplantation tolerance or the control of autoimmunity. To investigate whether nonlytic mAbs against CD40L induce tolerance to minor alloantigens in murine skin grafts, and whether linked suppression occurs in this system.

CBA/Ca mice treated perioperatively with MR1 demonstrated significant delay in graft rejection, but did not exhibit tolerance. This raised several questions. Were some cells involved in rejection not inhibited by anti-CD40L mAbs? Was the effect of MR1 temporary? Or was it permanent but new thymic emigres were becoming competent to reject? This led to the use of thymectomized mice in the study. These showed indefinite graft acceptance with MR1, but only following CD8⁺ T cell depletion. Thymectomized, CD4⁺ T cell depleted mice treated with MR1 showed delayed rejection (but not indefinite survival as in the athymic CD8⁺ T cell depleted animals). Tolerance was also induced in euthymic mice if MR1 was combined with anti-CD8 mAb. Studies of athymic, CD8⁺-cell-depleted CBA/Ca mice, treated with MR1 and first transplanted with B10.BR, showed subsequent long term acceptance of (AKR x B10.BR)F₁ grafts but rapid rejection of (AKR x CBA/Ca)F₁ grafts, showing that MR1-induced antigen-specific tolerance exhibited a dominant regulatory phenotype.

CD40 and CD40 ligand (CD40L) interactions play a critical role in regulating T-cell-dependent humoral immunity, the threshold for negative selection in the thymus and the induction of peripheral tolerance. Interruption of CD40/CD40L interaction in the periphery should increase the threshold for T cell and B cell activation, thereby decreasing autoreactivity or inducing transplantation tolerance. Clinical trials of anti-CD40L monoclonal antibodies (mAbs) are already in progress for active lupus. This study cautions that antibodies to CD40L alone may be insufficient to induce lasting tolerance, and that CD8⁺ T cell depletion is required. While this is true for alloantigens on a skin graft, it is possible that anti-CD40L mAb (MR1) or a different anti-CD40L antibody may successfully induce tolerance to the nuclear and cytoplasmic components that are prominent B cell autoantigens in lupus.

MR1 or placebo was administered perioperatively to CBA/Ca mice transplanted with multiple minor mismatched skin from B10.BR mice and the time to graft rejection measured. To investigate whether MR1 could induce tolerance in CD4⁺ T cells, CBA/Ca mice were thymectomized and depleted of CD8⁺ T cells. MR1, anti-CD4 mAb or no mAb was given perioperatively and B10.BR tailskin transplanted. After 70 days animals were rechallenged with a fresh graft. Further experiments to investigate the role of CD8 in rejection involved depletion of either CD4⁺ or CD8⁺ T cells in thymectomized CBA/Ca mice transplanted with B10.BR tailskin (half these mice were treated with MR1 as well). Seventy days after transplanting B10.BR tailskin, mice were rechallenged with a fresh B10.BR graft and a third party BALB/c graft. Finally, the development of linked suppression was assessed using athymic, CD8⁺-cell-depleted CBA/Ca mice transplanted with B10.BR under cover of MR1. They then received second grafts of (AKR x B10.BR)F₁ + CBA/Ca tailskin or (AKR x CBA/Ca)F₁+ B10.BR tailskin.

Affiliations

1. United Medical and Dental Schools of Guy's and St Thomas' Hospitals, London, UK

   • Frances Williams

Reprints and Permissions